Clinical Trials Browser

Phase 3 × Interventional × Recurrence × Clear all

NCT05552976 2026-03-17

SUCCESSOR-2

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT06615479 2026-03-17

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT07221253 2026-03-17

AB02

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

NCT05519085 2026-03-11

SUCCESSOR-1

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT06149286 2026-03-06

OLYMPIA-5

Phase 3 Recruiting

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT06551324 2026-03-04

MEVPRO-1

Phase 3 Recruiting

Prostatic Neoplasms, Recurrence

NCT07166094 2026-03-03

RAINFOL-03

Phase 3 Recruiting

Recurrence, Endometrial Neoplasms

NCT06760637 2026-03-02

FourLight-3

Phase 3 Recruiting

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT07138209 2026-02-27

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT05888493 2026-02-20

LEDA

Phase 3 Active not recruiting

Lymphoma, Follicular, Recurrence

NCT04094311 2026-02-17

Study of Out of Specification for Tisagenlecleucel

Phase 3 Recruiting

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07406542 2026-02-12

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

Phase 3 Not yet recruiting

Breast Neoplasms, Recurrence

NCT06522737 2026-02-11

TERZO

Phase 3 Recruiting

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Lymphoma, T-Cell, Peripheral

NCT06097364 2026-02-06

OLYMPIA-2

Phase 3 Active not recruiting

Lymphoma, Follicular, Recurrence

NCT04712097 2026-02-04

Celestimo

Phase 3 Active not recruiting

Lymphoma, Follicular, Recurrence

NCT07286162 2026-01-27

CALM-TF

Phase 3 Not yet recruiting

Ovarian Neoplasms, Recurrence

NCT06976190 2026-01-20

Magic-C002

Phase 3 Recruiting

Nasopharyngeal Carcinoma, Recurrence

NCT05455320 2026-01-16

MonumenTAL-3

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT02341989 2025-12-02

SWENOTECA-ABC

Phase 3 Active not recruiting

Recurrence, Testicular Neoplasms, Seminoma

NCT02390869 2025-12-02

FIL_RENOIR12

Phase 3 Active not recruiting

Lymphoma, Follicular, Recurrence

NCT03525873 2025-10-20

A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy

Phase 3 Active not recruiting

Neoplasm Metastasis, Recurrence

NCT04838613 2025-10-20

GuidePath

Phase 3 Completed

190 enrolled 25 charts

Prostatic Neoplasms, Recurrence

NCT07197580 2025-09-29

LUTEON

Phase 3 Not yet recruiting

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

NCT07011056 2025-09-19

A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma

Phase 3 Recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03981796 2025-09-03

RUBY

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

NCT03581786 2025-09-02

The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer

Phase 3 Completed

289 enrolled 32 charts 1 FDA

Recurrence

NCT03575351 2025-08-03

TRANSFORM

Phase 3 Completed

184 enrolled 30 charts 1 FDA

Lymphoma, Non-Hodgkin, Recurrence

NCT01952223 2025-07-30

PEACE2

Phase 3 Active not recruiting

Adenocarcinoma, Recurrence

NCT03539744 2025-06-19

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Phase 3 Active not recruiting

Multiple Myeloma, Neoplasms, Recurrence

NCT02804815 2025-06-10

Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours

Phase 3 Active not recruiting

11,000 enrolled

BreastGastrointestinalGenitourinary

Breast Neoplasms, Neoplasms, Prostatic Neoplasms, Recurrence, Colorectal Neoplasms

NCT05294172 2025-05-30

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT06064877 2025-04-13

FIERCE-HN

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Neoplasm Metastasis, Recurrence

NCT03765541 2025-04-10

DEXAML-03

Phase 3 Terminated

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT03257267 2025-04-08

Study of Cemiplimab in Adults With Cervical Cancer

Phase 3 Completed

608 enrolled 18 charts

Carcinoma, Squamous Cell, Neoplasm Metastasis, Recurrence

NCT03734016 2025-03-30

ALPINE

Phase 3 Completed

652 enrolled 27 charts 1 FDA

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05899465 2025-03-18

PRIME

Phase 3 Recruiting

Melanoma, Neoplasms, Recurrence

NCT05037279 2025-02-20

EVER

Phase 3 Recruiting

Urinary Bladder Neoplasms, Recurrence

NCT04939142 2025-02-11

BENCH

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT03924986 2025-01-31

RATIONALE-309

Phase 3 Completed

263 enrolled 19 charts

Nasopharyngeal Neoplasms, Recurrence

NCT05578976 2025-01-23

EPCORE DLBCL-2

Phase 3 Active not recruiting

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03138512 2024-12-18

CheckMate 914

Phase 3 Completed

1,641 enrolled 21 charts

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

NCT06561854 2024-12-18

FREEDOM

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT03836014 2024-12-06

CONFIRM

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT05726110 2024-10-22

Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia

Phase 3 Recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT04921527 2024-10-18

CHIPRO

Phase 3 Recruiting

Ovarian Neoplasms, Recurrence

NCT03110562 2024-08-21

BOSTON

Phase 3 Completed

402 enrolled 22 charts 2 FDA

Multiple Myeloma, Recurrence

NCT03859427 2024-08-13

ARROW2

Phase 3 Completed

454 enrolled 24 charts

Multiple Myeloma, Recurrence, Bone Marrow Neoplasms

NCT03464305 2024-03-19

ASPIRIN

Phase 3 Active not recruiting

Gastrointestinal

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Site, Pathologic Processes, Recurrence, Colorectal Neoplasms, Disease Attributes

NCT02013167 2024-03-05

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Phase 3 Terminated

405 enrolled 27 charts 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05910970 2024-01-23

PREVENT-2

Phase 3 Unknown

Gastrointestinal

Carcinoma, Hepatocellular, Recurrence